Description: Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Home Page: www.cogentbio.com
COGT Technical Analysis
200 Cambridge Park Drive
Cambridge,
MA
02140
United States
Phone:
617 945 5576
Officers
| Name | Title |
|---|---|
| Mr. Andrew R. Robbins M.B.A. | Pres, CEO & Director |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer |
| Mr. Brad Barnett | Chief Technology Officer |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corp. Sec. |
| Ms. Erin Schellhammer | Chief People Officer |
| Ms. Sara Saltzman | Sr. VP of Regulatory Affairs |
| Mr. Dana R. Martin Pharm.D. | Sr. VP of Medical Affairs & Chief Patient Officer |
| Brad Fell | VP & Head of Medicinal Chemistry |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4617 |
| Price-to-Sales TTM: | 1320.6301 |
| IPO Date: | 2018-03-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 121 |